Research programme: angiogenesis inhibitors - Allergan/Pharmacopeia

Drug Profile

Research programme: angiogenesis inhibitors - Allergan/Pharmacopeia

Alternative Names: PS388023; PS680648; PS780035

Latest Information Update: 06 Jul 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pharmacopeia Drug Discovery
  • Developer Allergan; Ligand Pharmaceuticals
  • Class 3-ring heterocyclic compounds; Benzimidazoles; Isoquinolines; Pyrimidines; Small molecules
  • Mechanism of Action Integrin alphaVbeta3 antagonists; Integrin alphaVbeta5 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Eye disorders

Most Recent Events

  • 23 Dec 2008 Pharmacopeia has been acquired by Ligand Pharmaceuticals
  • 12 Jul 2005 This programme has been licensed to Allergan worldwide for the treatment of eye disorders
  • 21 Jun 2005 Preclinical trials in Eye disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top